Synmosa (健喬) announced that Goofice (固腹順), an IBAT inhibitor licensed from Japan’s EA Pharma, is scheduled for Taiwan launch between April and June 2026. This marks the first-ever Ileal Bile Acid Transporter (IBAT) inhibitor available for chronic functional constipation in the region.

Market Context & Clinical Value:

• Mechanism: The active ingredient, Elobixibat, inhibits bile acid reabsorption in the ileum, increasing bile acid levels in the colon to stimulate natural bowel movements.
• Addressable Market: In Taiwan, over 1.4 million people seek treatment for constipation annually, with the market exceeding NT$800 million and growing at 6–8% per year.
• Portfolio Synergy: Goofice completes Synmosa’s gastrointestinal (GI) line, which already includes established brands like Kensianning (diarrhea) and Gaviscon (GERD), positioning the group as a comprehensive leader in GI health.

Resource: 健喬引進日本EA Pharma治療慢性便秘的IBAT抑制劑 第2季上市